Radiopharmaceuticals & Production
Generators, cyclotron products, cold kits, and radiochemical quality control
Quick Answer
A radiopharmaceutical pairs a radionuclide (signal/therapy source) with a targeting molecule (which determines biodistribution). Radionuclides come from generators (a long-lived parent decays to a short-lived daughter eluted on demand — Mo-99/Tc-99m, Ge-68/Ga-68, Sr-82/Rb-82), from cyclotrons (F-18, I-123, Cu-64, and many PET tracers), or from reactors (Mo-99 parent, I-131, Lu-177). Most Tc-99m agents are made on site by adding eluted pertechnetate to a cold kit, then verified by radiochemical purity testing before release.
Clinical Importance
Supply logistics shape practice: generator half-lives dictate elution schedules, cyclotron products must be produced/distributed within tight windows, and Mo-99 supply disruptions periodically threaten Tc-99m availability. Production also underpins quality — a mislabeled or impure preparation produces artifacts or non-diagnostic studies.
Sources of Radionuclides
| Source | How it works | Examples |
|---|---|---|
| Generator | Parent decays to eluted daughter | Mo-99→Tc-99m; Ge-68→Ga-68; Sr-82→Rb-82; Ac-225→(daughters) |
| Cyclotron | Charged-particle bombardment | F-18, I-123, Cu-64, N-13, C-11 |
| Reactor | Neutron activation / fission | Mo-99 (→Tc-99m), I-131, Lu-177 |
Generator Equilibria
- Transient equilibrium (parent half-life modestly longer than daughter): Mo-99 (66 h) → Tc-99m (6 h) — daughter activity regrows between elutions and slightly exceeds a simple parent-tracking curve.
- Secular equilibrium (parent half-life vastly longer): Ge-68 → Ga-68, Sr-82 → Rb-82 — daughter activity equals parent activity at equilibrium and the generator lasts a long time.
The Mo-99 / Tc-99m Generator
Tc-99m is the SPECT workhorse (140 keV γ, 6-hour half-life). Its Mo-99 parent (66 h) is eluted as pertechnetate; the daughter regrows between elutions. Elutions are tested for Mo-99 breakthrough (parent contamination) and aluminum (from the column). Pertechnetate is then combined with cold kits to make MDP, sestamibi, MAG3, MAA, sulfur colloid, and others.
Cold Kits & Labeling
A cold kit contains the ligand plus a reducing agent (stannous ion) in a sterile vial; adding Tc-99m-pertechnetate reduces and complexes the technetium to make the labeled agent. Labeling failures leave recognizable signatures:
- Free pertechnetate (incomplete reduction / oxidation): thyroid, stomach, salivary activity.
- Hydrolyzed-reduced technetium (excess stannous / hydrolysis): a liver/colloid pattern.
Quality Control
Before release: radiochemical purity (correct labeled species, e.g. by chromatography), radionuclidic purity (Mo-99 breakthrough, aluminum for the Tc generator), sterility/apyrogenicity for compounded products, and activity in a dose calibrator. PET and therapy radiopharmaceuticals have their own release specifications, and particle-size control matters for MAA and sulfur colloid (aggregates cause artifactual uptake).
Practical Supply Notes
- Ga-68 generators make site-flexible PSMA/DOTATATE PET; F-18 analogs allow centralized batch distribution.
- Short half-lives force rapid, sometimes real-time release testing.
- Mo-99 is reactor-produced with a fragile supply chain — periodic shortages force protocol substitutions.
Common Pitfalls
- Attributing a labeling artifact to disease (gastric free-pertechnetate mistaken for pathology).
- Ignoring Mo-99 breakthrough or aluminum limits on generator eluate.
- Particle-size problems (MAA/sulfur colloid) causing artifactual distribution.
- Assuming any PET tracer can be shipped — short-half-life agents (C-11, N-13, O-15) cannot.
Board Pearls
A generator holds a longer-lived parent that decays into a shorter-lived, useful daughter eluted on demand (daughter regrows between elutions) — how cyclotron-free sites make Tc-99m (Mo-99), Ga-68 (Ge-68), and Rb-82 (Sr-82). Distinguish transient (Mo-99/Tc-99m) from secular (Ge-68/Ga-68, Sr-82/Rb-82) equilibrium.
Two labeling-failure patterns to know cold: free pertechnetate → thyroid/stomach/salivary activity; hydrolyzed-reduced technetium → a liver/colloid pattern. Recognizing these prevents calling an artifact disease and prompts a repeat preparation.
Before release, preparations are checked for radiochemical purity (correct labeled species), radionuclidic purity (Mo-99 breakthrough, aluminum), and — for compounded/PET products — sterility/endotoxin, with short half-lives forcing rapid release testing. Particle-size control matters for MAA/sulfur colloid, and Ga-68 generators vs F-18 distribution explains site-flexible vs centralized PET supply.
Related Pages
- Related: Physics of nuclear medicine, radiation detection & instrumentation, PET radiochemistry & production, molecular imaging & the theranostic pair.
- Pitfalls: Pearls, pitfalls & normal variants (free-pertechnetate signature).
Figure / Diagram Suggestions
- A Mo-99/Tc-99m generator diagram (column, elution, regrowth curve).
- Transient vs secular equilibrium activity curves.
- A labeling-artifact plate (free pertechnetate vs hydrolyzed-reduced colloid pattern).
Self-Check (Board-Style)
Q1. A Tc-99m study shows thyroid, gastric, and salivary activity. What labeling problem does this indicate?
Answer: Free pertechnetate from incomplete reduction/oxidation of the preparation — its classic biodistribution signature. Repeat the preparation.
Q2. How does a Mo-99/Tc-99m generator provide Tc-99m without a cyclotron?
Answer: The long-lived Mo-99 parent decays to Tc-99m, which is eluted as pertechnetate on demand and regrows between elutions (transient equilibrium).
Q3. Which two contaminants are checked on Tc-99m generator eluate, and why?
Answer: Mo-99 breakthrough (radionuclidic purity — parent contamination adds dose and degrades images) and aluminum (from the column — can disrupt labeling, e.g. sulfur-colloid aggregation).
Q4. Why can F-18-FDG be shipped from a central cyclotron but C-11-choline cannot?
Answer: Half-life — F-18 (~110 min) tolerates distribution, whereas C-11 (~20 min) is too short-lived and needs an on-site cyclotron.
Evidence & sources
https://nuc.med/radiopharmaceuticals-overview/ Report an issue